Rafael C. Rosell
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 421 publications
Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.
Journal: Neoplasia (New York, N.Y.)
Published: July 10, 2026
Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial.
Journal: Journal for immunotherapy of cancer
Published: July 08, 2026
Experience of the implementation of a lung cancer screening program at the Hospital General de Catalunya (Barcelona, Spain).
Journal: Current problems in cancer
Published: June 26, 2026
Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 15, 2026
Drug repurposing in KRAS G12C-mutant NSCLC: a focus on resistance mechanisms and clinical strategies.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: April 15, 2026
Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 23, 2026
Expression of LIFR in tumor and SHOC2, YAP1 in plasma mRNA as potential biomarkers in KRAS G12C NSCLC.
Journal: Scientific reports
Published: February 19, 2026
Chemotherapy in combination with KRAS inhibitors in KRAS-mutated non-small cell lung cancer.
Journal: Journal of thoracic disease
Published: December 23, 2025
Author Correction: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial.
Journal: Nature communications
Published: December 12, 2025
Impact of TP53, KEAP1 and STK11 mutations in localized-stage NSCLC: A European thoracic oncology platform lungscape project.
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 04, 2025
Corrigendum to 'Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged non-small cell lung cancer' [Journal of Thoracic Oncology, Volume 19 Issue 1 (2024) 119-129].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 27, 2025
Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.
Journal: The Lancet. Oncology
Published: October 01, 2025
Last Updated: 09/26/2026